DK0443891T3 - Anvendelse af N-myristotyl-(S)-phenylalanin eller et additionssalt deraf med en farmaceutisk acceptabel base til opnåelse af et farmaceutisk middel og farmaceutisk middel til behandling af sygdomme ved indgribning i myristoyleringen - Google Patents

Anvendelse af N-myristotyl-(S)-phenylalanin eller et additionssalt deraf med en farmaceutisk acceptabel base til opnåelse af et farmaceutisk middel og farmaceutisk middel til behandling af sygdomme ved indgribning i myristoyleringen

Info

Publication number
DK0443891T3
DK0443891T3 DK91400163.1T DK91400163T DK0443891T3 DK 0443891 T3 DK0443891 T3 DK 0443891T3 DK 91400163 T DK91400163 T DK 91400163T DK 0443891 T3 DK0443891 T3 DK 0443891T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical
phenylalanine
diseases
treatment
myristotyl
Prior art date
Application number
DK91400163.1T
Other languages
Danish (da)
English (en)
Inventor
Michel Vincent
Georges Remond
Yolande Herve
Jean-Albert Boutin
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Application granted granted Critical
Publication of DK0443891T3 publication Critical patent/DK0443891T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK91400163.1T 1990-01-25 1991-01-25 Anvendelse af N-myristotyl-(S)-phenylalanin eller et additionssalt deraf med en farmaceutisk acceptabel base til opnåelse af et farmaceutisk middel og farmaceutisk middel til behandling af sygdomme ved indgribning i myristoyleringen DK0443891T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000834A FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.

Publications (1)

Publication Number Publication Date
DK0443891T3 true DK0443891T3 (da) 1993-12-27

Family

ID=9393082

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91400163.1T DK0443891T3 (da) 1990-01-25 1991-01-25 Anvendelse af N-myristotyl-(S)-phenylalanin eller et additionssalt deraf med en farmaceutisk acceptabel base til opnåelse af et farmaceutisk middel og farmaceutisk middel til behandling af sygdomme ved indgribning i myristoyleringen

Country Status (14)

Country Link
US (1) US5164414A (cg-RX-API-DMAC7.html)
EP (1) EP0443891B1 (cg-RX-API-DMAC7.html)
JP (1) JPH0717503B2 (cg-RX-API-DMAC7.html)
AT (1) ATE94387T1 (cg-RX-API-DMAC7.html)
AU (1) AU633395B2 (cg-RX-API-DMAC7.html)
CA (1) CA2034861A1 (cg-RX-API-DMAC7.html)
DE (1) DE69100364T2 (cg-RX-API-DMAC7.html)
DK (1) DK0443891T3 (cg-RX-API-DMAC7.html)
ES (1) ES2060310T3 (cg-RX-API-DMAC7.html)
FR (1) FR2657259A1 (cg-RX-API-DMAC7.html)
IE (1) IE65573B1 (cg-RX-API-DMAC7.html)
OA (1) OA09478A (cg-RX-API-DMAC7.html)
PT (1) PT96571A (cg-RX-API-DMAC7.html)
ZA (1) ZA91574B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672598A1 (fr) * 1991-02-11 1992-08-14 Adir Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5599947A (en) * 1993-01-14 1997-02-04 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US6407125B1 (en) 1995-12-29 2002-06-18 Novactyl, Inc. Pharmacological agent and method of treatment
US6127393A (en) 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6579891B1 (en) 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US6441009B1 (en) 1998-08-01 2002-08-27 Novactyl, Inc. Agent and method of preventing and treating heavy metal exposure and toxicity
WO2001037827A1 (en) * 1999-10-13 2001-05-31 Chacon Marco A Therapeutic intervention to mimic the effect of caloric restriction
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
WO2003007876A2 (en) * 2001-06-25 2003-01-30 University Of Massachusetts N-fatty acid-amino acid conjugates and therapeutic uses
DE10353806A1 (de) * 2003-11-14 2005-07-07 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
CN103826623A (zh) 2011-07-22 2014-05-28 厄尔莱克斯制药公司 合成致死与癌症的治疗
CN104254253B (zh) 2012-03-30 2017-12-29 奇华顿股份有限公司 作为食品加香化合物的n‑酰化甲硫氨酸衍生物
EP2830437B1 (en) 2012-03-30 2018-12-26 Givaudan SA N-acylated 1-aminocycloalkyl carboxylic acids as food flavouring compounds
BR112014023941B1 (pt) 2012-03-30 2020-07-14 Givaudan S.A. Composição flavorizante em pó, bem como composições comestíveis de petisco e refresco em pó compreendendo a mesma
WO2013148991A1 (en) 2012-03-30 2013-10-03 Givaudan S.A. N-acyl derivatives of gamma amino - butyric acid and and beta alanine as food flavouring compounds
EP2833739B1 (en) 2012-03-30 2020-12-02 Givaudan SA N-acyl proline derivatives as food flavouring compounds
KR102045589B1 (ko) 2012-03-30 2019-11-15 지보당 에스아 식품 향미 화합물로서의 n-아실-아미노산 유도체
CA2868085C (en) 2012-03-30 2020-09-15 Harry Renes Improvements in or relating to organic compounds
JP6463685B2 (ja) * 2012-10-30 2019-02-06 パシレックス・ファーマシューティカルズ・インコーポレイテッド 合成致死性および癌の治療
GB201317424D0 (en) 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
CN105658089B (zh) 2013-10-02 2019-07-09 奇华顿股份有限公司 有机化合物
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
US10834950B2 (en) 2013-10-02 2020-11-17 Givaudan S.A. Organic compounds
US11122826B2 (en) 2013-10-02 2021-09-21 Givaudan Sa Organic compounds
WO2015050534A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
WO2015048990A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
WO2015048991A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
JP7539760B2 (ja) 2015-07-17 2024-08-26 パシレックス・ファーマシューティカルズ・インコーポレイテッド Ｎｍｔ２の後成的なサイレンシング

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778878A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides I
US4778877A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides II

Also Published As

Publication number Publication date
ATE94387T1 (de) 1993-10-15
DE69100364D1 (de) 1993-10-21
ES2060310T3 (es) 1994-11-16
FR2657259B1 (cg-RX-API-DMAC7.html) 1994-08-19
DE69100364T2 (de) 1994-04-21
FR2657259A1 (fr) 1991-07-26
JPH04210916A (ja) 1992-08-03
ZA91574B (en) 1991-11-27
EP0443891B1 (fr) 1993-09-15
IE910242A1 (en) 1991-07-31
EP0443891A1 (fr) 1991-08-28
AU633395B2 (en) 1993-01-28
PT96571A (pt) 1991-10-15
CA2034861A1 (fr) 1991-07-26
US5164414A (en) 1992-11-17
JPH0717503B2 (ja) 1995-03-01
AU6998791A (en) 1991-08-01
OA09478A (fr) 1992-11-15
IE65573B1 (en) 1995-11-01

Similar Documents

Publication Publication Date Title
DK0443891T3 (da) Anvendelse af N-myristotyl-(S)-phenylalanin eller et additionssalt deraf med en farmaceutisk acceptabel base til opnåelse af et farmaceutisk middel og farmaceutisk middel til behandling af sygdomme ved indgribning i myristoyleringen
NO894296L (no) Fremgangsmaate for behandling av leddgikt og betennelsessykdommer.
DE59101397D1 (de) O-glycosyliertes ifn-alpha.
CA2083179A1 (en) Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
NO934500L (no) Ikke-klorfluorcarbonaerosolformuleringer
DK156098C (da) Thixotropt middel til brug ved fraktionering af blod
SE7606302L (sv) Uppresningsstol, speciellt hopfellbar uppresninsstol for invalider och sjuka
SE7905593L (sv) Acylderivat av karnitin och forfarande for framstellning derav
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
ES2071663T3 (es) Analogo de fluoxetina.
NO931413L (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
ES2120962T3 (es) Composicion antivirica.
NO913035D0 (no) (2r)-2-(di(2-propyl)fosfonylmetoksy)-3-p-toluensulfonyloksy-1-trimetylacetoksypropan, fremgangsmaate for fremstilling og anvendelse derav.
DK160816C (da) Benzoyl-urinstof-derivater, fremgangsmaade til fremstilling af disse, fremgangsmaade til bekaempelse af insektangreb samt insekticidt middel indeholdende disse
IT9020968A0 (it) Metodi e composizioni farmaceutiche per il trattamento di malattie oftalmiche
DK627289D0 (da) Anvendelse af bicyclononanderivater
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
DE59104783D1 (de) Patientenuntersuchungstisch.
FI911533A7 (fi) Bentsoksatsiini-johdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö sairauksien hoitamiseen tai ennalta ehkäisemiseksi
DK632388A (da) Pharmaceutisk middel til behandling af hyperlipidaemi hol pattedyr
HU9300388D0 (en) New medical preparatives with 5-(1-hydroxi-2-chlorine-ethyl)-4-methyl-triazole content and method for preparing them
MX9102325A (es) Formas de dosis farmaceuticas de almacalante y procedimiento para su obtencion.
DK0711163T3 (da) Anvendelse af benzydamin i behandlingen af patologiske tilstande forårsaget af TNF
NL7803642A (nl) Individuele endo-osseo inplant voor odonto-stomalogie (mondchirurgie) en werkwijze voor de snelle en perfek- te aanbrenging van de inplant in de patient.
DK670588D0 (da) Farmaceutisk praeparat til behandling af phlebektasi og fremgangsmaade til fremstilling af praeparatet